Table 6A.B.2.2: Frequency and Survivorship of Soft Tissue Cancers, by Subgroup, United States 2004-2015

			Probability of Survival at Stated Interval [1]			
			24 Month		60 Month	
Histology	Frequency Count	Percent of Total	Survival Distribution Function (SDF) Estimate	SDF 95% Confidence Interval	Survival Distribution Function (SDF) Estimate	SDF 95% Confidence Interval
Leiomyosarcoma, NOS	8,489	12.30	0.73	0.72-0.74	0.55	0.54-0.56
Sarcoma, NOS	5,643	8.18	0.54	0.53-0.56	0.43	0.41-0.44
Malignant fibrous histiocytoma	4,965	7.19	0.72	0.71-0.73	0.56	0.54-0.57
Giant cell sarcoma (except of bone M-9250/3)	4,179	6.05	0.67	0.65-0.68	0.51	0.49-0.53
Fibromyxosarcoma	3,297	4.78	0.89	0.88-0.90	0.77	0.76-0.79
Liposarcoma, well differentiated	3,286	4.76	0.95	0.94-0.96	0.88	0.87-0.90
Liposarcoma, myxoid	3,023	4.38	0.91	0.90-0.92	0.82	0.81-0.84
Spindle cell sarcoma	2,795	4.05	0.58	0.56-0.60	0.45	0.43-0.47
Malignant peripheral nerve sheath tumor	2,346	3.40	0.64	0.62-0.66	0.50	0.48-0.52
Hemangiosarcoma	2,235	3.24	0.41	0.39-0.43	0.25	0.23-0.27
Dermatofibrosarcoma, NOS	2,153	3.12	0.99	0.98-0.99	0.96	0.95-0.97
Liposarcoma, NOS	1,767	2.56	0.85	0.83-0.87	0.74	0.71-0.76
Liposarcoma, dedifferentiated	1,568	2.27	0.73	0.71-0.75	0.55	0.52-0.58
Synovial sarcoma, NOS	1,509	2.19	0.76	0.74-0.78	0.59	0.56-0.62
Synovial sarcoma, spindle cell	1,360	1.97	0.82	0.80-0.84	0.64	0.61-0.67
Undifferentiated sarcoma	1,131	1.64	0.63	0.60-0.66	0.50	0.46-0.53
Fibrosarcoma, NOS	1,069	1.55	0.79	0.76-0.81	0.64	0.61-0.68
Liposarcoma, pleomorphic	1,061	1.54	0.74	0.71-0.77	0.55	0.52-0.58
Ewing sarcoma	998	1.45	0.73	0.71-0.76	0.61	0.58-0.64
Epithelioid sarcoma	945	1.37	0.68	0.65-0.71	0.55	0.51-0.58
Rhabdomyosarcoma, alveolar	898	1.30	0.65	0.62-0.68	0.41	0.37-0.44
Rhabdomyosarcoma, embryonal, NOS	828	1.20	0.79	0.76-0.81	0.67	0.64-0.71
Synovial sarcoma, biphasic	686	0.99	0.90	0.88-0.92	0.74	0.70-0.78
Neuroblastoma, NOS	679	0.98	0.87	0.85-0.90	0.79	0.75-0.82
Chondrosarcoma, myxoid	647	0.94	0.84	0.81-0.87	0.73	0.69-0.76
Rhabdomyosarcoma, NOS	630	0.91	0.55	0.51-0.59	0.38	0.33-0.42
Myxosarcoma	511	0.74	0.82	0.79-0.86	0.70	0.66-0.75
Desmoplastic small round cell tumor	431	0.62	0.55	0.50-0.60	0.18	0.14-0.23
Clear cell sarcoma, NOS (excluding kidney)	426	0.62	0.68	0.63-0.72	0.51	0.46-0.56
Liposarcoma, mixed	412	0.60	0.84	0.81-0.88	0.69	0.64-0.74
Rhabdomyosarcoma, pleomorphic adult type	405	0.59	0.49	0.44-0.54	0.34	0.29-0.39
Solitary fibrous tumor, malignant	394	0.57	0.79	0.75-0.84	0.64	0.58-0.70
Osteosarcoma, NOS	365	0.53	0.61	0.55-0.66	0.44	0.38-0.49
Chondrosarcoma, NOS	362	0.52	0.83	0.79-0.87	0.72	0.67-0.77
Liposarcoma, round cell	313	0.45	0.79	0.75-0.84	0.62	0.56-0.67
Alveolar soft part sarcoma	312	0.45	0.79	0.74-0.83	0.61	0.55-0.67
Primitive neuroectodermal tumor, NOS	303	0.44	0.67	0.62-0.72	0.51	0.45-0.57
Small cell sarcoma	303	0.44	0.53	0.47-0.59	0.44	0.38-0.50
Hemangiopericytoma, malignant	290	0.42	0.83	0.79-0.88	0.75	0.69-0.80
Peripheral neuroectodermal tumor	262	0.38	0.73	0.67-0.78	0.57	0.50-0.63
Neoplasm, malignant	250	0.36	0.46	0.39-0.52	0.35	0.28-0.41
Ganglioneuroblastoma	197	0.29	0.99	0.97-1.00	0.96	0.92-0.99
Leiomyosarcoma, epithelioid	194	0.28	0.69	0.62-0.75	0.51	0.43-0.59
Epithelioid hemangioendothelioma, malignant	179	0.26	0.73	0.66-0.79	0.65	0.57-0.72
Leiomyosarcoma, myxoid	175	0.25	0.74	0.68-0.81	0.51	0.43-0.59
Pseudosarcomatous carcinoma	172	0.25	0.26	0.19-0.33	0.21	0.15-0.27
Malignant rhabdoid tumor	134	0.19	0.43	0.34-0.52	0.32	0.23-0.41
Malignant myoepithelioma	133	0.19	0.84	0.78-0.91	0.69	0.60-0.78
Rhabdomyosarcoma, spindle cell	131	0.19	0.69	0.61-0.77	0.51	0.42-0.60
Teratoma, malignant, NOS	129	0.19	0.85	0.79-0.91	0.84	0.77-0.90
Chordoma, NOS	122	0.18	0.86	0.79-0.92	0.71	0.62-0.80
Chondrosarcoma, mesenchymal	117	0.17	0.76	0.68-0.84	0.66	0.56-0.75

Table 6A.B.2.2: Frequency and Survivorship of Soft Tissue Cancers, by Subgroup, United States 2004-2015

			Probability of Survival at Stated Interval [1]			
			24 Month		60 Month	
Histology	Frequency Count	Percent of Total	Survival Distribution Function (SDF) Estimate	SDF 95% Confidence Interval	Survival Distribution Function (SDF) Estimate	SDF 95% Confidence Interval
Malignant peripheral nerve sheath tumor, rhab	112	0.16	0.52	0.42-0.61	0.42	0.32-0.52
Neurilemoma, malignant [obs]	111	0.16	0.83	0.75-0.90	0.70	0.61-0.80
Malignant tumor, spindle cell type	92	0.13	0.59	0.49-0.69	0.47	0.36-0.58
Neuroendocrine carcinoma, NOS	78	0.11	0.74	0.64-0.85	0.64	0.52-0.76
Fibrosarcoma, infantile	73	0.11	0.95	0.89-1.00	0.93	0.86-0.99
Paraganglioma, malignant	69	0.10	0.77	0.67-0.87	0.54	0.40-0.68
Rhabdomyosarcoma, mixed type	62	0.09	0.71	0.59-0.82	0.54	0.41-0.68
Malignant tenosynovial giant cell tumor	61	0.09	0.97	0.92-1.00	0.77	0.62-0.92
Chondrosarcoma, dedifferentiated	57	0.08	0.46	0.33-0.60	0.25	0.12-0.38
Myosarcoma	57	0.08	0.75	0.63-0.86	0.48	0.33-0.63
Hemangioendothelioma, malignant	52	0.08	0.63	0.49-0.77	0.43	0.27-0.60
Osteosarcoma, chondroblastic	52	0.08	0.57	0.44-0.71	0.39	0.24-0.53
Dermatofibrosarcoma protuberans, pigmented	45	0.07	1.00	1.00-1.00	0.97	0.91-1.00
Malignant giant cell tumor of soft parts	45	0.07	0.84	0.72-0.95	0.78	0.65-0.91
Mesenchymoma, malignant	45	0.07	0.61	0.46-0.75	0.44	0.26-0.61
Stromal sarcoma, NOS	44	0.06	0.76	0.64-0.89	0.70	0.56-0.85
Glomus tumor, malignant	39	0.06	0.95	0.87-1.00	0.73	0.55-0.91
Synovial sarcoma, epithelioid cell	27	0.04	0.67	0.49-0.84	0.58	0.39-0.77
Total	66,330	96.12	0.73	0.72-0.73	0.58	0.58-0.59

[1] Example: The probability of survival at 24 months from diagnosis for Leiomyosarcoma, NOS is 73% (95% confidence interval 72% to 74%) and at 60 months, it is 55% (95% confidence interval 54% to 56%).

Source: The National Cancer Data Base (NCDB) of the American College of Surgeons (ACS), 2004-2015.